Compare Elastic NV (ESTC) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elastic NV vs Novo Nordisk A/S — how do they compare? Elastic NV trades at $98.23 (market cap $10.00B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 16.5× Elastic NV's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Elastic NV pays none. Which is the better fit depends on your goals — on Pluang, investors hold Elastic NV for 10 Days and Novo Nordisk A/S for 116 Days on average.
| ESTC | NVO | |
|---|---|---|
Market Cap | $10.00B | $165.31B |
Volume | 1,610,337 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $99.91 | $63.98 |
52-Week Low | $43.30 | $35.29 |
Typical Hold Time | 10 Days | 116 Days |
Enterprise Value | $9.14B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $98.23, up 5.51% today, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent product launches, including AI-driven metrics and serverless vector database offerings, highlight innovation in observability and search. Revenue growth is projected to increase from $1.48B in 2025 to $1.8B in 2026, with net income turning positive to $376M.
The outlook is positive given earnings momentum and strategic product expansions, though high valuation ratios and insider selling pose risks. The consensus price target of $79.50 suggests potential downside from current levels, but bullish technicals and institutional interest support a constructive view. Key risks include competitive pressures and execution challenges in scaling new AI integrations.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
